Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

被引：0

作者：

Sehn, Laurie H. ^{[1
,2
]}

Luminari, Stefano ^{[3
,4
]}

Scholz, Christian W. ^{[5
]}

Huebel, Kai ^{[6
,7
,8
]}

Salar, Antonio ^{[9
]}

Paneesha, Shankara ^{[10
,11
]}

Wahlin, Bjorn E. ^{[12
]}

Panayiotidis, Panayiotis ^{[13
]}

Lee, Hui-Peng ^{[14
]}

Ubieto, Ana Jimenez ^{[15
]}

Sancho, Juan-Manuel ^{[16
]}

Kim, Tae Min ^{[17
]}

Domenech, Eva Domingo ^{[18
]}

Kumode, Takahiro ^{[19
]}

Poh, Christina ^{[20
]}

Thieblemont, Catherine ^{[21
]}

Deeren, Dries ^{[22
]}

de Wit, Edwin ^{[23
]}

Arbushites, Michael ^{[24
]}

Casadebaig, Marie-Laure ^{[23
]}

Trneny, Marek ^{[25
,26
]}

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Modena & Reggio Emilia, Oncol & Regenerat Med, Surg Med & Dent Morphol Sci Related Transplant, Reggio Emilia, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] Vivantes Klinikum Urban, Berlin, Germany

[6] Univ Cologne, Cologne, Germany

[7] Univ Hosp Cologne, Fac Med, Cologne, Germany

[8] Univ Hosp Cologne, Cologne, Germany

[9] Hosp Mar IMIM, Barcelona, Spain

[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[11] Univ Birmingham, Birmingham, England

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Natl & Kapodistrian Univ Athens, Gen Hosp LAIKO, Med Sch, Athens, Greece

[14] Flinders Med Ctr, Adelaide, Australia

[15] Hosp 12 Octubre, Serv Hematol, Madrid, Spain

[16] Univ Autonoma Bacrcelona, ICO IJC Hosp Germans Trias & Pujol, Barcelona, Spain

[17] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[18] Hosp Duran I Reynals, IDIBELL, Inst Catala Oncol, Barcelona, Spain

[19] Kindai Univ, Osaka, Japan

[20] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[21] St Paris Cite Univ, St Hosp, Assistance Publ Hop Paris, Paris, France

[22] AZ Delta Gen Hosp, Roeselare, Belgium

[23] Incyte Int Biosci, Sarl Morges, Switzerland

[24] Incyte Corp, Wilmington, DE USA

[25] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[26] Gen Hosp, Prague, Czech Republic

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-212970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA1 / LBA4

页数：4

共 50 条

[31] MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
Nastoupil, Loretta J.
Song, Yuqin
Sehn, Laurie Helen
Sarkozy, Clementine
Zinzani, Pier Luigi
Silvestre, Antonio Salar
Zhang, Jun
Huang, Sha
Wang, Julie
Delarue, Richard
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Wang, M.
Fowler, N.
Wagner-Bartak, N.
Feng, L.
Romaguera, J.
Neelapu, S. S.
Hagemeister, F.
Fanale, M.
Oki, Y.
Pro, B.
Shah, J.
Thomas, S.
Younes, A.
Hosing, C.
Zhang, L.
Newberry, K. J.
Desai, M.
Cheng, N.
Badillo, M.
Bejarano, M.
Chen, Y.
Young, K. H.
Champlin, R.
Kwak, L.
Fayad, L.
LEUKEMIA, 2013, 27 (09) : 1902 - 1909
[33] Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.
Fowler, Nathan Hale
Neelapu, Sattva Swarup
Samaniego, Felipe
Forbes, Sheryl
Hagemeister, Fredrick B.
Fayad, Luis
Feng, Lei
Turturro, Francesco
Westin, Jason R.
Arafat, Janine
Neal, Eleanor
Nastoupil, Loretta J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[34] Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
Wang, Yucai
Wagner-Bartak, Nicolaus
Zhou, Shouhao
Fowler, Nathan
Dela Rosa, Maria Lourdes
Zhao, Donglu
Romaguera, Jorge E.
Neelapu, Sattva S.
Hagemeister, Fredrick B.
Fanale, Michelle A.
Oki, Yasuhiro
Shah, Jatin J.
Thomoas, Sheeba K.
Hosing, Chitra M.
Zhang, Liang
Badillo, Maria
Chen, Wendy
Cai, Qingqing
Zou, Dehui
Champlin, Richard E.
Fayad, Luis E.
Lee, Hun Ju
Wang, Michael
BLOOD, 2015, 126 (23)
[35] HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Stevens, Wendy B. C.
Bakunina, Katerina
Cuijpers, Marloes
Chamuleau, Martine
Beeker, Aart
Fijnheer, Rob
Hebart, Holger
Visser, Hein P. J.
Doorduijn, Jeanette K.
Linton, Kim
Dreyling, Martin
de Jong, Daphne
Kersten, Marie Jose
HEMASPHERE, 2020, 4 (01):
[36] Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma
Li, Cong
Hu, Huixian
Lei, Tao
Yu, Haifeng
Chen, Xi
Peng, Shuailing
Han, Shuiyun
Yang, Haiyan
BLOOD, 2023, 142
[37] Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis
Zhang, Peng-Fei
Xie, Dan
Wen, Feng
Li, Qiu
CANCER MEDICINE, 2020, 9 (15): : 5312 - 5319
[38] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
Fowler, Nathan
Kahl, Brad S.
Lee, Peter
Matous, Jeffrey V.
Cashen, Amanda F.
Jacobs, Samuel A.
Letzer, Jeffrey
Amin, Bipinkumar
Williams, Michael E.
Smith, Sonali
Saleh, Alfred
Rosen, Peter
Shi, Hongliang
Parasuraman, Sudha
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395
[39] A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
Cheson, Bruce D.
Crawford, Jeanette
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 528 - 533
[40] A complete response to tafasitamab and lenalidomide in a patient with refractory grade 3B follicular lymphoma.
Germain, M.
Lampenfeld, J.
Safah, H.
Saba, N. S.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 365 : S369 - S369

← 1 2 3 4 5 →